+96.5%
STM vs MRNA
+945.0%
-848.5%
-44.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -6.1% | +13.1% | -19.2% | -6.2% |
| 7D | -6.0% | +20.6% | -26.7% | -6.2% |
| 30D | -20.9% | +27.1% | -48.1% | -21.1% |
| 3M | -15.8% | +353.4% | -369.1% | -18.3% |
| 6M | -17.0% | +446.3% | -463.3% | -24.0% |
| YTD | +76.8% | +776.2% | -699.4% | +44.4% |
| 1Y | +96.5% | +987.9% | -891.4% | +48.1% |
| All | +96.5% | +945.0% | -848.5% | +48.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling